Compare Rivian Automotive, Inc. (RIVN) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rivian Automotive, Inc. vs Sanofi SA — how do they compare? Rivian Automotive, Inc. trades at $16.04 (market cap $23.41B), while Sanofi SA trades at $43.12 (market cap $104.06B). The key difference: Sanofi SA is far larger — about 4.4× Rivian Automotive, Inc.'s market cap, and Sanofi SA pays a 5.61% dividend while Rivian Automotive, Inc. pays none. Which is the better fit depends on your goals.
| RIVN | SNY | |
|---|---|---|
Market Cap | $23.41B | $104.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $22.45 | $52.34 |
52-Week Low | $12.50 | $41.33 |
Enterprise Value | $23.45B | $124.09B |
Dividend Yield | — | 5.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rivian Automotive (RIVN) trades at $16.17, up 2.73% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $18.70. The company continues to report significant net losses but has shown improvement in revenue growth and gross profit margins, while recent news highlights strong demand for the R2 SUV and advancements in autonomy capabilities.
The outlook for RIVN hinges on successful R2 production scaling and path to profitability, with upside potential from current levels but high execution risk amid competitive EV market pressures and persistent cash burn requiring ongoing financing.
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
